Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2012

View Archived Issues

Afatinib demonstrates significant improvements in PFS in the LUX-lung 3 phase III trial

Korean researchers patent novel antiviral compositions

Janssen Pharmaceutica presents new BACE1 inhibitors

Treventis prepares new anti-amyloid compounds

Novel cannabinoid CB1 receptor allosteric modulators discovered at University of Aberdeen

New efflux pump inhibitors for bacterial infections disclosed

Theravance presents new dual MABA bronchodilators for COPD

Ten major pharma companies form nonprofit organization

Almirall launches aclidinium in Europe

Cancer Therapeutics CRC synthesizes novel FADK inhibitors

Bayer submits European MAA for contraceptive patch

Identification of a new series of potent and selective NS5B inhibitors

Patrys cleared to commence phase I/IIa PAT-SM6 study

Murdoch Children's Research Institute receives grant to fight rotavirus

Intercell reports outcome of vaccine enhancement patch study in influenza

Plasma serotonin as indicator of stable heart disease outcomes

Scripps Research Institute receives grant for HIV research

The Leukemia & Lymphoma Society to support BET inhibitor program

Bayer College of Medicine presents novel Ndufs4-mutant mouse model

Sanofi and the TB Alliance to accelerate tuberculosis drug discovery

Cytochroma begins first of two identical phase III studies of CTAP-101

FDA approves sNDA for Aerospan inhalation aerosol

Dyax grants Kadmon exclusive license for anticancer candidate

Second phase I study confirms GAL-021's effects on respiration

Biovest provides update on planned MAA for NHL vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...